SH
SHPH.US Shuttle Pharmaceuticals Inc
- Market cap
- USD 18.7M
- P/E
- -
- P/B
- 1.13x
- ROE
- -55.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is SHPH.US undervalued?
Graham numberThe Graham number of Shuttle Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shuttle Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Shuttle Pharmaceuticals Inc yet.
Shuttle Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shuttle Pharmaceuticals Inc
Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to treat cancers. It owns a pharmaceutical software artificial intelligence (AI) driven platform for molecular discovery and early-stage drug development. The company was founded in 2012 and is headquartered in Gaithersburg, Maryland.
Full company profileShuttle Pharmaceuticals Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Shuttle Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2015 | 2016 | 2017 | 2018 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | - | - | -18.7K | -18.0K | -55.0K | -60.8K | -5.97K | -6.81K | -5.46K | -290K | - |
| Operating Income | - | - | -204K | -587K | -510K | -1.74M | -2.34M | -5.89M | -7.70M | -11.9M | -12.3M |
| EBITDA | - | - | -184K | -577K | -711K | -1.04M | -4.32M | -3.99M | -7.78M | -11.4M | -9.65M |
| Net Income | - | - | -214K | -626K | -806K | -1.15M | -5.00M | -6.59M | -9.14M | -11.7M | -10.6M |
| EPS | - | - | -0.16 | -0.46 | -0.59 | -0.85 | -4.83 | -4.14 | -8.86 | -72 | -10 |
| Balance Sheet | |||||||||||
| Total Assets | - | - | 121K | 621K | 544K | 652K | 8.65M | 5.95M | 2.51M | 10.5M | 22.8M |
| Total Liabilities | - | - | 406K | 594K | 2.23M | 2.28M | 976K | 1.90M | 1.80M | 8.22M | 3.63M |
| Shareholders' Equity | - | - | -284K | 27.5K | -1.69M | -1.63M | 7.68M | 4.06M | 709K | 2.25M | 19.2M |
| Cash & Short-term Investments | - | - | 50.7K | 352K | 117K | 505K | 8.42M | 5.46M | 1.92M | 334K | 90.2K |
| Total Debt | - | - | 314K | 400K | 874K | 979K | 748K | 1.09M | 1.17M | 232K | 195K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -304K | -230K | -203K | -567K | -26.8K | -300K | -2.71M | -5.58M | -7.33M | -9.48M | -5.97M |
| Capital Expenditure | 4.55K | 4.55K | 0.00 | 10.8K | 10.8K | 4.00 | 0.00 | 19.0K | 19.0K | 5.00 | 144K |
| Free Cash Flow | - | - | -203K | -567K | -37.6K | -300K | -2.71M | -5.60M | -7.33M | -9.48M | -5.90M |
| Ratios | |||||||||||
| ROE | - | - | - | -2,280.5% | - | - | -65.1% | -162.6% | -1,289.5% | -519.9% | -55.2% |
| ROA | - | - | -176.1% | -100.8% | -148.1% | -176.8% | -57.7% | -110.8% | -364.9% | -111.9% | -46.5% |
| Debt to Equity | - | - | - | 14.57x | - | - | 0.10x | 0.27x | 1.65x | 0.10x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Shuttle Pharmaceuticals Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 402K | 0.39 | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
| 2016 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:10 on Jun 11, 2026.
Who owns Shuttle Pharmaceuticals Inc
- Insiders 0.84%
- Institutions 0.87%
- Public & others 98.28%
- Shares outstanding 4.76M
- Free float 4.76M
Top funds holding SHPH.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 14.6K | 0.31% | -0.37% | Sep 2026 |
Top institutions holding SHPH.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| HRT FINANCIAL LLC | 78.6K | 1.65% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 24.4K | 0.51% | 0.00% | Jun 2026 |
| Barclays PLC | 750.00 | 0.02% | 0.00% | Jun 2026 |
| Tower Research Capital LLC | 389.00 | 0.01% | -16.16% | Jun 2026 |
| Wall Street Access Asset Management, LLC | 120.00 | 0.00% | +100.00% | Jun 2026 |
| Ikarian Capital, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Geode Capital Management, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Virtu Financial LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| BOOTHBAY FUND MANAGEMENT, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| UBS Group AG | 0.00 | 0.00% | -100.00% | Jun 2026 |
Shuttle Pharmaceuticals Inc company profile
- Company name
- Shuttle Pharmaceuticals Inc
- Ticker
- SHPH.US
- Exchange
- USA Stocks
- Listed since
- Aug 31, 2022
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2
- Fiscal year end
- December
- Address
- 401 Professional Drive, Gaithersburg, MD, United States, 20879
- Phone
- 240 403 4212
- Website
- shuttlepharma.com
About Shuttle Pharmaceuticals Inc
Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to treat cancers. It owns a pharmaceutical software artificial intelligence (AI) driven platform for molecular discovery and early-stage drug development. The company was founded in 2012 and is headquartered in Gaithersburg, Maryland.
Shuttle Pharmaceuticals Inc management
7- Mr. Christopher Robert Cooper BBA, M.B.A.Interim Co-CEO & Director · born 1970
- Dr. Milton Brown CSC, M.D., Ph.D.Co-Founder · born 1965
- Mr. Ryan TrasoliniCo-Chief Executive Officer
- Dr. Mira Jung Ph.D.Co-Founder & Chief Scientific Officer for Biology · born 1949
- Ms. Yuying Liang B.A., CPAChief Financial Officer · born 1991
- Dr. Tyvin A. Rich M.D.Chief Clinical Officer & Chief Medical Officer · born 1948
- Mr. Michael P. Vander HoekVice President for Operations and Regulatory · born 1960